Physician profile
Kee Bin No
NPI 1811902596
$2,202.76
in general payments reported to CMS, 2019-2025
19 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $19.49 · 2021: $96.94 · 2022: $240 · 2023: $461 · 2024: $556 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $590.13 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $255.61 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $210.08 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $205.20 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $187.42 | 2020-2025 | |
| Mylan Specialty L.P. | $142.97 | 2022-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $102.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.10 | 2024-2025 | |
| Amgen INC. | $82.95 | 2024-2025 | Otezla, Repatha, Prolia |
| Abbvie INC. | $79.87 | 2023-2024 | |
| Glaxosmithkline, LLC. | $63.28 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.84 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $34.53 | 2023-2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $21.37 | 2021 | |
| Tactile Systems Technology INC | $20.39 | 2025 | Flexitouch Plus, Nimbl |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.56 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.80 | 2025 | Zoryve |
| Convatec INC. | $16.58 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kee No listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.